Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis

Masahiro Miura1 Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ami, Ibaraki, Japan;2 Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, JapanCorrespondence[email protected]

Takuya Iwasaki1 Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ami, Ibaraki, Japan;2 Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, Japan

Hiroshi Goto2 Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, Japan

Pages 1591-1595 | Published online: 07 Aug 2013

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

YannuzziLASorensonJSpaideRFLipsonBIdiopathic polypoidal choroidal vasculopathy (IPCV)Retina (Philadelphia, Pa)199010118
PubMed Web of Science ®Google Scholar
LaudeACackettPDVithanaENPolypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?Prog Retin Eye Res2010291192919854291
PubMed Web of Science ®Google Scholar
GomiFOhjiMSayanagiKOne-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patientsOphthalmology2008115114114617582498
PubMed Web of Science ®Google Scholar
HikichiTHiguchiMMatsushitaTOne-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patientsAm J Ophthalmol20121541117124. e122465366
PubMed Web of Science ®Google Scholar
AkazaEYuzawaMMoriRThree-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathyJpn J Ophthalmol2011551394421331691
PubMed Web of Science ®Google Scholar
BinderSLoss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?Br J Ophthalmol20129611222157632
PubMed Web of Science ®Google Scholar
EghøjMSSørensenTLTachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumabBr J Ophthalmol2012961212321733918
PubMed Web of Science ®Google Scholar
HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
PubMed Web of Science ®Google Scholar
PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis201215217118522302382
PubMed Web of Science ®Google Scholar
PatelKHChowCCRathodRRapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumabEye (Lond)2013275663667 quiz 66823558214
PubMed Web of Science ®Google Scholar
MitchellPKorobelnikJFLanzettaPRanibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trialsBr J Ophthalmol201094121319443462
PubMed Web of Science ®Google Scholar
StewartMWRosenfeldPJPredicted biological activity of intravitreal VEGF TrapBr J Ophthalmol200892566766818356264
PubMed Web of Science ®Google Scholar
BrownDMMichelsMKaiserPKHeierJSSyJPIanchulevTANCHOR Study GroupRanibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR studyOphthalmology200911615765. e519118696
PubMed Web of Science ®Google Scholar
GasperiniJLFawziAAKhondkaryanABevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisationBr J Ophthalmol2012961142021791509
PubMed Web of Science ®Google Scholar
ChongVBiological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factorsOphthalmologica2012227Suppl 121022517120
PubMed Web of Science ®Google Scholar
RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
PubMed Web of Science ®Google Scholar
LeungDWCachianesGKuangWJGoeddelDVFerraraNVascular endothelial growth factor is a secreted angiogenic mitogenScience19892464935130613092479986
PubMed Web of Science ®Google Scholar
NagyJABenjaminLZengHDvorakAMDvorakHFVascular permeability, vascular hyperpermeability and angiogenesisAngiogenesis200811210911918293091
PubMed Web of Science ®Google Scholar
HikichiTHiguchiMMatsushitaTResults of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathyBr J Ophthalmol201397561762123428984
PubMed Web of Science ®Google Scholar
RakicJMLambertVDevyLPlacental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularizationInvest Ophthalmol Vis Sci20034473186319312824270
PubMed Web of Science ®Google Scholar
ZhangFTangZHouXVEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesisProc Natl Acad Sci USA2009106156152615719369214
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date